Table 2.
Comparison of clinical data in groups positive and negative for CD33 and CD13.
| Clinical parameters |
CD33 Mean or number (%) |
CD13 Mean or number (%) |
||||
|---|---|---|---|---|---|---|
| Negative (N = 44) |
Positive (N = 10) |
P | Negative (N = 18) |
Positive (N = 20) |
P | |
| Age | 61.2 | 61.1 | 0.978 | 61.9 | 60.4 | 0.688 |
| Calcium (mg/dL) | 9.03 | 9.78 | 0.049 | 9.03 | 9.60 | 0.145 |
| Creatinine (mg/dL) | 1.36 | 1.28 | 0.710 | 1.32 | 1.50 | 0.434 |
| Albumin (mg/dL) | 3.81 | 3.55 | 0.270 | 3.66 | 3.91 | 0.243 |
| β2-Microglobulin (mg/dL) | 4.76 | 4.71 | 0.966 | 3.09 | 4.28 | 0.635 |
| Hemoglobin (g/dL) | 10.6 | 9.8 | 0.277 | 10.3 | 10.6 | 0.687 |
| LDH (U/L) | 172 | 369 | 0.018 | 140 | 302 | 0.078 |
| Monoclonal heavy chain | 0.793 | 0.454 | ||||
| IgG | 24 (77) | 7 (23) | 12 (60) | 8 (40) | ||
| IgA | 10 (91) | 1 (9) | 2 (29) | 5 (71) | ||
| IgD | 3 (100) | 0 (0) | 1 (33) | 2 (67) | ||
| Light chain only | 7 (29) | 2 (71) | 3 (38) | 5 (52) | ||
| Monoclonal light chain | 0.603 | 0.207 | ||||
| Kappa | 27 (82) | 6 (18) | 9 (39) | 14 (61) | ||
| Lambda | 17 (81) | 4 (9) | 9 (60) | 6 (40) | ||
| BM aspirate plasma cell (%) | 38 | 48 | 0.903 | 36 | 48 | 0.198 |
| Plasma cell type | 0.022 | 0.519 | ||||
| Mature | 35 (90) | 4 (10) | 14 (54) | 12 (46) | ||
| Immature | 4 (50) | 4 (50) | 2 (29) | 5 (71) | ||
| Plasmablastic | 1 (50) | 1 (50) | 0 (0) | 1 (100) | ||
| Pleomorphic | 4 (80) | 1 (20) | 2 (50) | 2 (50) | ||
| Infiltration pattern | 0.487 | 0.046 | ||||
| Interstitial | 14 (88) | 2 (12) | 5 (100) | 0 (0) | ||
| Focal | 2 (67) | 1 (33) | 1 (50) | 1 (50) | ||
| Diffuse | 28 (80) | 7 (20) | 12 (44) | 15 (56) | ||
| Cytogenetics (FISH)‡ | ||||||
| t(4;14) | 7/40 | 1/4 | 0.566 | 3/18 | 4/19 | 0.532 |
| 1q amplification | 14/39 | 4/7 | 0.258 | 6/18 | 9/19 | 0.297 |
| 13q deletion | 14/39 | 4/7 | 0.258 | 5/18 | 8/19 | 0.286 |
| 17p deletion | 2/33 | 0/7 | 0.677 | 0/15 | 2/15 | 0.241 |
| Cytogenetic high risk group¶ | 9/35 | 1/7 | 0.461 | 3/16 | 6/16 | 0.217 |
| International staging system | 0.742 | 0.647 | ||||
| Stage I | 19 (86) | 3 (14) | 6 (43) | 8 (57) | ||
| Stage II | 14 (78) | 4 (22) | 6 (43) | 8 (57) | ||
| Stage III | 11 (79) | 3 (21) | 6 (60) | 4 (40) | ||
| Durie-Salmon stage | 0.753 | 0.766 | ||||
| Stage I | 5 (100) | 0 (0) | 2 (67) | 1 (33) | ||
| Stage II | 9 (82) | 2 (18) | 3 (38) | 5 (62) | ||
| Stage III | 30 (77) | 9 (23) | 13 (48) | 14 (52) | ||
| IMWG risk | 0.867 | 0.791 | ||||
| Low | 8 (82) | 1 (18) | 3 (60) | 2 (40) | ||
| Standard | 30 (79) | 8 (21) | 12 (46) | 14 (54) | ||
| High | 6 (86) | 1 (14) | 3 (43) | 4 (47) | ||
| IMWG response | 0.742 | 0.698 | ||||
| Complete response | 8 (80) | 2 (20) | 4 (50) | 4 (50) | ||
| Very good partial response | 6 (86) | 1 (14) | 2 (40) | 3 (60) | ||
| Partial response | 10 (83) | 2 (17) | 5 (71) | 2 (29) | ||
| Stable disease | 1 (50) | 1 (50) | 1 (100) | 0 (0) | ||
| Progressive disease | 5 (71) | 2 (29) | 3 (43) | 4 (57) | ||
BM: bone marrow; LDH: lactate dehydrogenase; IMWG: International Myeloma Working Group; ‡numbers of positive cases among FISH tests done; percentages were not written because meanings were different from that of other parameters; ¶including t(4;14) or del(17p).